Azenta's price target already looks reached with a negative risk/reward setup, and quality metrics sit below the engine's floor amid margin compression and a recent earnings miss streak, though a momentum recovery and positive insider buying offer some offsetting signals.
Thesis pillars
- Quality Below Floor Value Trap→Stable
- Target Reached Negative Asymmetry→Stable
- Overbought Bear Rally Downtrend→Stable
- +2 more pillars — see the Why tab for full reasoning
Azenta, Inc. (AZTA) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $24.50: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 21%; Elevated put/call ratio: 3.30; Below-average business quality.
Azenta is a global provider of biological and chemical sample exploration and management solutions for the life sciences industry, operating through two segments: Sample Management Solutions (automated cold-chain storage, cryogenic systems, sample repository services) and... Read more
Sell if holding. Engine safety override at $24.50: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 21%; Elevated put/call ratio: 3.30; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 59. Score 5.0/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 28d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
About Azenta, Inc.
About Azenta, Inc.
Azenta serves approximately 14,000 customers in roughly 95 countries through two segments, Sample Management Solutions and Multiomics, operating a network of 14 genomic-services laboratories (seven in the United States, three in China, two in the United Kingdom, and one each in Japan and Germany) alongside automated cold-chain storage systems that hold samples from ambient temperatures down to -190°C. The company divested its founding semiconductor automation business for $2.9 billion in February 2022 and is now pursuing the sale of its B Medical Systems refrigeration unit to concentrate on its two remaining life-sciences segments.
Azenta's Sample Management Solutions segment earns revenue from Sample Repository Services (on-site and off-site cold-chain storage, logistics, and informatics) and Core Products such as automated stores, cryogenic freezers, sample tubes, and consumables, sold mostly through a direct sales force supplemented by distributors for consumables and emerging markets. The Multiomics segment sells gene sequencing, gene synthesis, and bioinformatics services, competing against BGI Genomics, Eurofins, GenScript, Integrated DNA Technologies, Novogene, and Twist Bioscience, while Sample Management Solutions competes with Hamilton Company, Liconic, Laboratory Corporation of America, and Thermo Fisher Scientific. Manufacturing is concentrated at two major facilities, in Missouri and in Manchester and Wotton, United Kingdom, and the company held approximately $119.6 million of cash denominated in foreign currency as of September 30, 2025, a substantial share of its total cash position.
Show full overview
Azenta's genomic-services footprint carries geopolitical exposure through China: three of its 14 genomic laboratories and one of its sample-storage sites are located in Beijing and other Chinese locations, and the 10-K specifically flags the risk of lost revenue and damaged customer relationships in China from escalating U.S.-China trade tensions and tariffs, on top of broader supply-chain risk from reliance on single-source suppliers. Azenta also disclosed in April 2026 that Ginger Zhou departed as President of its Multiomics segment, with Maravai LifeSciences' former CEO William Martin installed as her successor the same day, a leadership change in the segment most exposed to the China-sourcing and trade-policy risks described above.
See also: Healthcare · Medical Instruments & Supplies
From Azenta, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-07Item 5.02MEDIUMGinger Zhou stepped down as President of the Multiomics business effective April 6, 2026, with no disagreement with the company cited; she continues as a consultant through November 2026. William 'Trey' Martin III, former CEO of Maravai LifeSciences, was appointed as her successor effective the same day.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -29.1%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.50: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 21%; Elevated put/call ratio: 3.30; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 59. Prior stop was $22.79. Score 5.0/10, moderate confidence.
Take-profit target: $26.51 (+8.2% upside). Prior stop was $22.79. Stop-loss: $22.79.
Target reached (-7.0% upside); Quality below floor (3.9 < 4.0); Value-trap signals (3/5): Margin compression (op margin -54.5%), Material insider selling (50 sells, 0.15% of cap), Negative free cash flow.
Azenta, Inc. trades at a P/E of N/A (forward 41.8). TrendMatrix value score: 5.1/10. Verdict: Sell.
13 analysts cover AZTA with a consensus score of 3.9/5. Average price target: $26.
What does Azenta, Inc. do?Azenta is a global provider of biological and chemical sample exploration and management solutions for the life...
Azenta is a global provider of biological and chemical sample exploration and management solutions for the life sciences industry, operating through two segments: Sample Management Solutions (automated cold-chain storage, cryogenic systems, sample repository services) and Multiomics (gene sequencing and synthesis services). The company serves approximately 14,000 customers across roughly 95 countries and is pursuing the sale of its B Medical Systems refrigeration business to sharpen its focus on those two core segments.